Shanghai Universal Biotech Co.,Ltd. (SHE:301166)
China · Delayed Price · Currency is CNY 33.03
+0.86 (2.67%)
At close: Sep 23, 2026
SHE:301166 Revenue
Shanghai Universal Biotech had revenue of 309.23M CNY in the quarter ending June 30, 2026, with 7.20% growth. This brings the company's revenue in the last twelve months to 1.15B, up 7.23% year-over-year. In the year 2025, Shanghai Universal Biotech had annual revenue of 1.08B, down -3.05%.
Revenue (ttm)
1.15B
Revenue Growth
+7.23%
P/S Ratio
2.45
Revenue / Employee
1.38M
Employees
810
Market Cap
2.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.08B | -34.05M | -3.05% |
| Dec 31, 2024 | 1.12B | -108.07M | -8.82% |
| Dec 31, 2023 | 1.23B | 30.70M | 2.57% |
| Jan 1, 2023 | 1.20B | 85.46M | 7.70% |
| Jan 1, 2022 | 1.11B | 260.59M | 30.69% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Baolingbao Biology | 2.85B |
| Beijing Kawin Technology Share-Holding | 1.23B |
| Shandong Sito Bio-technology | 1.12B |
| Zhejiang East Asia Pharmaceutical | 990.47M |
| Guangdong VTR Bio-Tech | 814.07M |
| Hubei Goto Biopharm Group | 650.05M |
| Zhejiang Shouxiangu Pharmaceutical | 616.54M |
| Suzhou Fushilai Pharmaceutical | 394.29M |